Proacta's lead drug, PR104, is a hypoxia-selective small-molecule prodrug designed to improve the outcome of cancer patients by targeting cancer cells resistant to current treatments. PR104 is being evaluated in a phase I/II clinical trial in patients with relapsed or recurrent Acute Leukemia.

Proacta's preclinical program is focused on hypoxia-selective prodrugs of tyrosine kinase inhibitors. Drugs under development in our preclinical program are intended to treat drug-resistance solid tumors, in particular, Non Small Cell Lung Cancer.

News at Proacta

• TV7 in New Zealand releases documentary on Proacta's HSMKI program

  

  24 August 2011
  
• Proacta Incorporated and Yakult Honsha Announce Expansion of their Collaborative Research, Development and Commercialization Agreement
  3 August 2011
  
• Proacta Incorporated and Yakult Honsha Announce an Agreement for the Collaborative Research, Development and Commercialization for Proacta’s PR509 Compound
  22 February 2011
  
• Proacta Inc receives $489,000 from US government stimulus for biotechnology
  1 December 2010